腹主动脉穿透性动脉粥样硬化性溃疡的系统综述:血管腔内修复的结局
该系统综述检索CENTRAL、MEDLINE和Web of Science数据库,纳入16项研究共165例接受血管腔内治疗的腹主动脉穿透性动脉粥样硬化性溃疡患者。汇总技术成功率为99.0%,30天死亡率为1.0%,随访期间死亡16例(9.7%)、再干预5例(3.3%)。作者认为短期看似安全有效,但中期和长期数据缺乏,研究质量低。
要点
- 汇总技术成功率为99.0%(95%CI 96.0%-100%)。
- 30天死亡率为1.0%(95%CI 0%-6.0%),院内死亡率为1.0%(95%CI 0.0%-13.0%)。
- 随访期间死亡16例(9.7%)、再干预5例(3.3%)、1型内漏3例(1.8%)、3型内漏1例(0.6%)。
核心结论
- 关于腹主动脉穿透性动脉粥样硬化性溃疡血管腔内修复结局的证据水平低。
- 短期血管腔内修复似乎安全有效,但缺乏中期和长期数据。
- 对无症状性穿透性动脉粥样硬化性溃疡的治疗指征和技术推荐应谨慎做出。
研究设计与样本
- 系统综述,按照PRISMA-P 2020方案进行,方案注册于PROSPERO(CRD42022313404)。
- 检索CENTRAL、MEDLINE(通过PubMed)和Web of Science数据库。
- 纳入报告3例及以上患者血管腔内修复穿透性动脉粥样硬化性溃疡技术和临床结局的研究。
- 共纳入16项研究,165例患者,平均/中位年龄范围为64至78岁,接受血管腔内治疗的时间为1997年至2020年。
- 采用随机效应模型估计汇总技术成功率、生存率、再干预以及1型和3型内漏,使用I²统计量评估统计异质性,研究质量采用改良Coleman方法学评分改编版评估。
主要发现
- 汇总技术成功率为99.0%(95%CI 96.0%-100%)。
- 30天死亡率为1.0%(95%CI 0%-6.0%),院内死亡率为1.0%(95%CI 0.0%-13.0%)。
- 30天时无再干预、无1型内漏、无3型内漏。
- 中位/平均随访时间为1至33个月。
- 随访期间共死亡16例(9.7%)、再干预5例(3.3%)、1型内漏3例(1.8%)、3型内漏1例(0.6%)。
关键数值与推荐
- 汇总技术成功率为99.0%(95%CI 96.0%-100%)。
- 30天死亡率为1.0%(95%CI 0%-6.0%),院内死亡率为1.0%(95%CI 0.0%-13.0%)。
- 随访期间死亡16例(9.7%)、再干预5例(3.3%)、1型内漏3例(1.8%)、3型内漏1例(0.6%)。
- 改良Coleman方法学评分平均为43.4(±8.5)分(总分85分),研究质量评为低。
临床怎么用
- 作者认为,短期腹主动脉穿透性动脉粥样硬化性溃疡血管腔内修复似乎安全有效,但中期和长期数据缺乏。
- 作者认为,鉴于无症状性穿透性动脉粥样硬化性溃疡的良性预后以及当前报告缺乏标准化,对无症状性穿透性动脉粥样硬化性溃疡的治疗指征和技术推荐应谨慎做出。
局限性
- 关于腹主动脉穿透性动脉粥样硬化性溃疡血管腔内修复结局的证据水平低。
- 缺乏中期和长期数据。
- 研究质量根据改良Coleman评分评为低,为85分中的43.4(±8.5)分。
- 当前报告缺乏标准化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To systematically review existing evidence on outcomes of endovascular repair of abdominal atherosclerotic penetrating aortic ulcers (PAUs). MATERIAL AND METHODS: Cochrane Central Registry of Registered Trials (CENTRAL), MEDLINE (via PubMed), and Web of Science databases were systematically searched. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis protocol (PRISMA-P 2020). The protocol was registered in the international registry of systematic reviews (PROSPERO CRD42022313404). Studies reporting on technical and clinical outcomes of endovascular PAU repair in 3 or more patients were included. Random effects modeling was used to estimate pooled technical success, survival, reinterventions, and type 1 and type 3 endoleaks. Statistical heterogeneity was assessed using the I2 statistic. Pooled results are reported with 95% confidence intervals (CIs). Study quality was assessed using an adapted version of the Modified Coleman Methodology Score. RESULTS: Sixteen studies including 165 patients with a mean/median age ranging from 64 to 78 years receiving endovascular therapy for PAU between 1997 and 2020 were identified. Pooled technical success was 99.0% (CI: 96.0%-100%). In all, 30-day mortality was 1.0% (CI: 0%-6.0%) with an in-hospital mortality of 1.0% (CI: 0.0%-13.0%). There were no reinterventions, type 1, or type 3 endoleaks at 30 days. Median/mean follow-up ranged from 1 to 33 months. Overall, there were 16 deaths (9.7%), 5 reinterventions (3.3%), 3 type 1 (1.8%), and 1 type 3 endoleak (0.6%) during follow-up. The quality of studies was rated low according to the Modified Coleman score at 43.4 (+/- 8.5) of 85 points. CONCLUSION: There is low-level evidence on outcomes of endovascular PAU repair. While in the short-term endovascular repair of abdominal PAU seems safe and effective, mid-term and long-term data are lacking. Recommendations with regard to treatment indications and techniques in asymptomatic PAU should be made cautiously. CLINICAL IMPACT: This systematic review demonstrated that evidence on outcomes of endovascular abdominal PAU repair is limited. While in the short-term endovascular repair of abdominal PAU seems safe and effective, mid-term and long-term data are lacking. In the context of a benign prognosis of asymptomatic PAU and lacking standardization in current reporting, recommendations with regard to treatment indications and techniques in asymptomatic PAUs should be made cautiously.
引用
- Hatzl J, Böckler D, Fiering J, et al. Systematic Review on Abdominal Penetrating Atherosclerotic Aortic Ulcers: Outcomes of Endovascular Repair. J Endovasc Ther. 2023. PMID: 36869667. doi:10.1177/15266028231157636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。